

THE MANAGEMENT OF HEAD INJURY

F. Gerstenbrand and M. Marosi

*University Clinic Innsbruck/Department of Neurology, Anichstraße 35,
6020 Innsbruck, Switzerland.*

More than half a million craniocervical injuries were recorded in 1986 in the states of the common market. Over 50 % of them were caused by traffic accidents and about 25 % by accidents at work. Increasing severity of the trauma indicates a higher probability of concomitant head injury, which will become, in more than 50 % of cases, the main injury. Patients after head injury, with decreased consciousness or coma, show different stages of a traumatic midbrain syndrome or bulbar-brain syndrome. Worsening of the clinical feature is connected with the involvement of lower brainstem structures due to the increasing intracranial pressure (ICP) caused by a primary lesion itself, or, as a consequence, by the secondary lesion (Tab. 1,2).

Primary lesions after brain injury


- cortical contusion
- brain laceration
- intracerebral/extracerebral
bleeding (ICH, SDH, EDH, SAN)
- periventricular lesions
- rhexis of corpus callosum
- brainstem contusion

secondary lesions after brain injury

- ischemia by shock
- perifocal/local brain edema
- >local/diffuse brain atrophy
- >tentorial/foraminal herniation
- >local midbrain lesion
- >ischemic local lesions
by strangled arteries
- >haemorrhage due to passive
hyperemia

Tab. 1 & 2: Primary and secondary lesions after brain injury.

The clinical feature of the acute midbrain syndrome shows two forms of development due to the pathomechanism of the herniation (Fig. 1 below).



PATHOMECHANISM OF..

- > uncal herniation
- > central (medial) herniation

Both, the uncal and the central herniation lead to a characteristic sequence of symptoms, which are dependent on the level of the lesion at the brain stem. The medial (central) herniation: Increasing general pressure induces pressure of the medial parts of the temporal lobe on to the upper brain stem. This induces a downward displacement of the brain stem structures. This transtentorial herniation leads to local direct pressure of the brain stem structures, strangulation of the arteries with ischemia and haemorrhages due to passive hyperemia. Due to this progressive lesioning of brain stem structures, a disengagement of brain stem functions of cortical control is effected. Therefore cortical uncontrolled mesencephalic primitive motor patterns, disturbances of vegetative functions, optomotoric and of the ascending reticular system with typical postures, disturbed eye movements and position, vegetative symptoms and consciousness occur.





Fig. 2: Typical symptoms of MBS 3 (central herniation)

The uncal herniation: The consequence of a local pressure on the brain is the uncal herniation, also with characteristic features. It is described as the first and second stage of lateralisation of acute midbrain syndrome - LMBS 1 & 2. These lateralized midbrain syndrome phases show a typical homolateral lesion of the nervus oculomotorius and a contralateral lesion of the midbrain structures, which are pressed to the edge of the tentorium. The second phase of LMBS is followed by a medial midbrain syndrome stage 4, but with remaining pupillar difference as a residual marker of lateralisation (Fig. 3). Insistent increased ICP causes herniation into the foramen magnum, with lesion and disintegration of the bulbar brain and the clinical feature of bulbar brain syndrome (Fig. 4).



COMA
 HOMOLATERAL WIDE PUPIL WITH
 NO REACTION TO LIGHT
 EXTENSION UPPER & LOWER LIMBS HOMOLATERAL
 FLEXION UPPER AND EXTENSION LOWER LIMBS
 KONTRALATERAL

	MBS I	MBS II A	MBS II B	MBS III	MBS IV	MBS I	MBS II
CONSCIOUSNESS	AWAKE	DOZE	COMA	COMA	COMA	COMA	COMA
REACTION TO ACOUSTIC STIMULI	PROUD	REDUCED	MISSING	MISSING	MISSING	MISSING	MISSING
REACTION TO PAIN	PROMPT	REDUCED	REDUCED	FLEXION & EXTENSION	EXTENSION	REST OF EXTENSION	SPINDLE
EYE POSITION	NORMAL	NORMAL	(DIVERGENT) DISTURBED CONJUGATION	DIVERGENT	DIVERGENT	FIXED DIVERGENT	FIXED DIVERGENT
EYE MOVEMENT	SWIFTING	REDUCED	REDUCED	MISSING	MISSING	MISSING	MISSING
PUPIL SIZE	⊙ ⊙	⊙ ⊙	⊙ ⊙	⊙ ⊙	⊙ ⊙	⊙ ⊙	⊙ ⊙
PUPIL REACTION TO LIGHT	⊙ ⊙	⊙ ⊙	⊙ ⊙	⊙ ⊙	⊙ ⊙	⊙ ⊙	⊙ ⊙
POSTURE	⌞	⌞	⌞	⌞	⌞	⌞	⌞
SPONTANEOUS MOVEMENTS	WALLING	WALLING	WALLING	EXTENSION LEG	EXTENSION UPPER & LOWER LIMBS	REST OF MBS IV	ATONIC
MUSCLE TONE	NORMAL	↑ LEG	↑ LEG	↑	↑	↑	—
BAROMBI	⌞	(⌞)	(⌞)	⌞	⌞	(⌞)	—
RESPIRATORY	⌞	⌞	⌞	⌞	⌞	⌞	—
BLOOD PRESSURE	NORMAL	NORMAL	NORMAL	(⌞)	⌞	NORMAL	⌞
TEMPERATURE	NORMAL	NORMAL	(⌞)	⌞	⌞	⌞	NORMAL TO ⌞





Fig.: 3,3a,4
 symptoms of lateralized midbrain syndrome 2
 symptomatology of MBS 1 to BBS 2
 development of central and uncus herniation

The first step of the therapy of severe head injury with the symptomatology of a midbrain syndrome should be the reanimation phase with coma monitoring, stabilisation of organ function and the differentiation between primary (intracranial hemorrhage) and secondary lesions (local or diffuse edema). One of the most important factors for a successful treatment but also for the first steps of rehabilitation is the initiation of therapy at the earliest stage of midbrain syndrome. Therefore the diagnose of the cause of the herniation then the clinical feature with coma monitoring becomes the time decisive factor. The progressive slipping off to lower stages of midbrain has to be stopped as early as possible. In our experiences diffuse brain edema seems to be the most

dangerous factor after brain trauma, with a frightening by fast slipping off into midbrain syndrome stage 4 or bulbar brain syndrome, especially in young patients.



FORMS OF
CEREBRAL EDEMA

1. vasogenic edema
affects mostly the white matter
the form of edema after brain
injury
2. cytotoxic edema
ICV increase of neurons and
glia in the gray matter
3. interstitial edema
diffusion of a vasogenic edema
from a local lesion into regions
with intact barriers

Fig. 5: Forms of cerebral edema.

For the reduction of ICP a decrease of the volume of each intracranial compartment - spinal fluid, extra- and intracellular volume - is aimed for. For the therapy of brain edema the use of general therapeutic measures such as sufficient ventilation, special head-trunk position and balanced arterial pressure, beside that hyperventilation, osmotic agents, barbiturates and steroids proved to be sufficient (Tab. 3, Tab. 4).

The use of osmotic agents is bound to intact barrier between extra- and intracellular volume (blood-brain barrier). The disadvantage of the therapy with osmotic agents and especially with polyvalent alcohol substances is a rebound phenomenon, which is caused by metabolism of the substance in the intracellular volume. The consequence is a disarrangement of the solvent drag into the cell. Renal problems will occur when reaching a osmolarity above 320 mosmol/kg. As a side effect of sorbitol (specially in combination with hyperventilation) lactat acidosis can be seen in some cases (Tab. 5, Tab. 6).

Barbiturates, possibly, have an effect on the metabolism of brain cells and also a direct effect on the cerebral vessels. EEG control (burst suppression) seems to be the best technique for ascertaining the required loading dose of the barbiturate, but a randomized clinical study is not known by the authors (Tab. 7).

THERAPY OF BRAIN EDEMA	GENERAL THERAPEUTIC MEASURES	DIURETICS
1. GENERAL THERAPEUTIC MEASURES	1. SUFFICIENT VENTILATION	FUROSEMID
2. HYPERVENTILATION	PaCO ₂ not > 42mmHg	0.25-0.30 mg /kg iv.
3. OSMOTIC AGENTS	PaO ₂ not < 80mmHg	ACETACOLAMIDE
4. BARBITURATES	2. HEAD / TRUNK POSITION	5-20 mg /kg iv
5. DIURETICS	ELEVATED AT 30°	not useful as monotherapy
6. STEROIDS	3. AVOIDANCE OF INCREASE OR DECREASE OF ARTERIAL PRESSURE	STERIODS
		dexamethason
		100 mg loading dose
		4-8 mg / 6h continuing
	OSMOTIC AGENTS	BARBITURATES
HYPERVENTILATION	MANNITOL 20%	pentobarbital cone
PaCO ₂ 25-30mmHg	50-100ml in about 15min iv./5h	3-5 mg /kg loading dose
PaO ₂ 75-80mmHg	SORBITOL 40%	1 mg /kg continued
CONTRACTION OF CEREBRAL VESSELS	0.5-2 g/kg iv in about 30min	Chiopentone
INCREASING BLOOD SUPPLY	CAVE: lactic acidosis	15-20 mg / kg loading dose
IN THE LESIONED AREA	GLYCERIN 10%	5 mg /kg/h for the next 6h
	0.2 g/kg/h iv	2-3 mg /kg/h following
	nearly without side effects	
	GLUCOSE 50% (obsolet)	
	FRUCTOSE 40% (obsolet)	
	LAEVULOSE 40% (obsolet)	
	UREA	
	5-16 mg/min iv	
	CAVE: problems with coagulation	
	hemoglobinuria	

Tab. 3,4,5,6,7 therapy of the acute midbrain syndrome

An acute midbrain syndrome or lateralized midbrain syndrome (see also Fig.4) can desintegrate to bulbarbrain syndrome or brain death, but also develop to a prolonged midbrain syndrome (specially from MBS 2b, 3 or 4) or to an apallic syndrome with 3 intermediate stages (coma prolonge, parasomnia, akinetic mutism). A reintegration is possible from a deep stage of traumatic midbrain syndrome with remittance of symptoms.

More often a prolonged midbrain syndrome or a apallic syndrome develops. The prolonged midbrain syndrome but also the

apallic syndrome show seven stages of remission, ending in a "defect stage" with remaining symptoms or a restitutio (in 17% of cases with apallic syndrome) Fig.: 5. The development of the apallic syndrome is characterized by typical clinical symptoms, Tab.: 8, but also by the onset of a overactivity of the sympathetic nervous system. The clinical problems, which occur now we subsummarize as tertiary and quartary lesions after brain injury Tab.: 9,10. The first signs of a remission should be seen within the first 4-5 month after the trauma, in default whereof the prognose is bad.

Without special treatment the sympathetic catabolic situation leads to marasm and severe peripheral and central nervous system lesions. Even high caloric nutrition can not stop this. The plasma level of norepinephrine is extremly high in these patients. Treatment with beta blocking agents and debrisoquine supresses the catabolic drive and allows a normocaloric nutrition. The basic principles of the programme for rehabilitation, which almost should beginn at the time of the intensive care, we show in Tab.:11

SYMPTOMS OF THE
APALLIC SYNDROME

coma vigile
missing emotional reaction
primitive motor pattern
fixed posture
increased sympathotonus
regulated rythm of phases of sleep
and wakeness

Tab.:8 clinical symptoms of an apallic syndrome

TERTIARY LESIONS
AFTER BRAIN INJURY

origin: malnutrition
malabsorption
electrolyte dybalance
hypovitaminosis
neuroendocrine dysfunction
superinfection

-->encephalopathy
-->pontine myelinolyse
-->myelopathy
-->neuropathy

QUARTARY LESIONS
AFTER BRAIN INJURY

hydrocephalus aresorptivus
hyeroma
abscess
meningoencephalitis per continui-
tatem or embolic
KOMPLIKATIONS
decubitus
contractures
periarticular ossifications

Tab.: 9,10 tertiary and quartary lesions after brain injury




Fig.: 5

PROGRAMME FOR REHABILITATION

I. CARE

EARLY DIAGNOSE AND PREVENTION
OF QUARTARY LESIONS

II. NUTRITION

USING BETA - BLOCKERS 2500-3000kcal/d
WITHOUT 5000-7000kcal
(toxic complications)

IV. PHYSICAL THERAPY

VI. ERGOTHERAPY

VIII. RESOCIALISATION

III. PHARMACOLOGICAL TREATMENT

BETA BLOCKERS

HGH (only to use after Arginin
stimulation test)

DOPA-SUBSTITUTION

ANTISPASTICS

ANTIEPILEPTICS

BRAIN METABOLISM

ACTIVATING SUBSTANCES AND

VITAMIN B

V. STIMULATING METHODS

VII. LOGOPEDIC TREATMENT

IX. PSYCHOLOGICAL

SUPPORTMENT

HGH

HGH LEVELS ARE LOW IN ALL PATIENTS WITHOUT SPECIFIC STIMULATION
AFTER ARGININ STIMULATION HGH RELEASE INCREASES IN PATIENTS
WITH MBS II AND III, BUT NOT IN PATIENTS WITH MBS IV OR APALLIC
SYNDROME

TREATMENT OF SPASTICITY

TIZANIDINE 6-12 mg /d

BACLOPHEN 45-75 mg /d

BENZODIAZEPINE

DANTROLENE

Tab.: 11

NEW TRENDS IN CLINICAL NEUROPHARMACOLOGY

**Calcium antagonists, acute neurology, headache
and movement disorders**

Proceedings of the Vth European Workshop on
Clinical Neuropharmacology, Bratislava, July 6-8, 1987

Edited by

**DANIEL BARTKO
PETER TURČÁNI
GERALD STERN**



British Library Cataloguing in Publication Data
European Workshop on Clinical Neuropharmacology
(5th: 1987: Bratislava, Czechoslovakia)
New trends in clinical neuropharmacology
1. Man. Nervous system. Drug Therapy
I. Title II. Bartko, Daniel III. Turčáni, Peter
IV. Stern, Gerald V. Series
616.8'0461

ISBN 0-86196-146-3

First published in 1988 by
John Libbey & Company Ltd
80/84 Bondway, London SW8 1SF, England. (01) 582 5266
John Libbey Eurotext Ltd
6 rue Blanche, 92129 Montrouge, France. (1) 47 35 85 52

© John Libbey & Company Ltd. 1988 All rights reserved
Unauthorized duplication contravenes applicable laws.

Typesetting by E. E. Owens & Co Ltd.
Printed in Great Britain by
Whitstable Litho Printers Ltd, Whitstable, Kent.